News

News 13.08.2026 Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability  Schlieren (Zurich), Switzerland, August 13, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2026. Financial Highlights Total Medical Device sales...

News 10.08.2026 CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that its fully-owned Swiss subsidiary, Proteomedix AG (“PMX”), has appointed Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting of Shareholders held...

News 30.07.2026 DINMIQS is welcoming Sabine Kuratli. Sabine joined at the beginning of this month as our new Head of Manufacturing & MSAT. With more than 20 years of experience in biopharmaceutical development, GMP manufacturing and Manufacturing Science & Technology (MSAT), Sabine brings extensive expertise in developing and executing CMC strategies, process development, technology...

News 28.07.2026 Schlieren, Switzerland, 21 July 2026 – arcoris bio, a Swiss life science research tools and in vitro diagnostics company, today announced a distribution partnership with Europa Biosite, a leading distributor of life science research products and services. Through this partnership, Europa Biosite will distribute arcoris bio’s newly launched immunoMUSE® kits in...

News 22.07.2026 Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront. The transaction provides the company access to non-dilutive funding for the development of its R&D pipeline. “Neurimmune’s financial strategy is based on non-dilutive income...